In an announcement published on 21 May 2026, Eli Lilly shared the results of the TRIUMPH-1 study, which involved 2,339 participants who were randomised to receive either retatrutide 4mg, 9mg, 12mg (building up every four weeks from 2mg), or placebo
Inclinical trials for GLP-1s, 3% of adults reported hair loss compared to 1% taking a placebo
Circulation (2011) 124(21):233849
FDA-Regulated Quality: Medications are sourced from an FDA-regulated 503B compounding pharmacy, ensuring the highest standards of safety and effectiveness
We still face several challenges: We need large-scale, randomized controlled trials specifically in RA, psoriasis, and PsA populations We need to understand the long-term effects of these drugs in autoimmune conditions We need to determine the optimal dosing and treatment duration for these new indications What This Means for You: A Personal Note As your rheumatologist, my primary concern is your well-being
Try our free insurance checker here
